Log in to search using one of your social media accounts:

 

Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers
In this report, we explain the seminal changes in the 8th edition of the Tumor-Node-Metastasis staging system for urologic cancers. Major stage category definitional changes are in Tumor-Node-Metastasis classifications of testicular, penile, and prostate cancer which improve patient stratification for prognosis and management. Refining the standards that provide the best possible staging system is a never-ending process. The 8th edition continues in that tradition with a more focused attempt to incorporate nonanatomic factors into staging. This approach is most evident in staging of prostate cancers where nonanatomic facto...
Source: European Urology - January 9, 2018 Category: Urology & Nephrology Source Type: research

Hyperaccuracy Three-dimensional Reconstruction Is Able to Maximize the Efficacy of Selective Clamping During Robot-assisted Partial Nephrectomy for Complex Renal Masses
Conclusions Preoperative simulation of selective ischemia was feasible and effective with HA3D reconstruction. In all the RAPN cases performed, selective clamping was successful, avoiding ischemia of the healthy renal remnant. A strict collaboration between urologists and bioengineers is mandatory to improve the technology. Patient summary In this report, we found that an accurate three-dimensional reconstruction of the kidney before conservative surgery for renal cancer seems to help in avoiding the global ischemia of the kidney. Further studies are needed to conclude if avoiding a percentage of ischemia to the kidney is ...
Source: European Urology - January 7, 2018 Category: Urology & Nephrology Source Type: research

Multiparametric Magnetic Resonance Imaging for Prostate-specific Antigen Recurrence After Radical Prostatectomy: Are We Leaving the “One Treatment Fits All Approach” and Moving Towards Personalized Imaging-guided Treatment?
Publication date: Available online 3 January 2018 Source:European Urology Author(s): Martin Spahn, Jean-Luc Fehr (Source: European Urology)
Source: European Urology - January 4, 2018 Category: Urology & Nephrology Source Type: research

Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation
Publication date: Available online 3 January 2018 Source:European Urology Author(s): Douglas Brand, Chris ParkerTeaser In men with prostate-specific antigen failure after radical radiotherapy, androgen deprivation therapy should be delayed until the site of recurrence is known to allow consideration of curative treatment options, to delay androgen deprivation therapy-related morbidity, and to enable earlier access to abiraterone and docetaxel. (Source: European Urology)
Source: European Urology - January 4, 2018 Category: Urology & Nephrology Source Type: research

Androgen Receptor Variants and Castration-resistant Prostate Cancer: Looking Back and Looking Forward
Publication date: Available online 3 January 2018 Source:European Urology Author(s): Takuma Uo, Cynthia Sprenger (Source: European Urology)
Source: European Urology - January 4, 2018 Category: Urology & Nephrology Source Type: research

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial
Conclusions Two-year postradiotherapy prostate biopsies have limited value in patients with PSA control but both positive biopsy and higher PSA status are strongly associated with future bPFS events. A policy of selected biopsy may provide an opportunity for early salvage interventions. Patient summary Routine 2-yr postradiotherapy biopsy is not recommended but can be considered in selected patients with unfavourable post-treatment prostate-specific antigen levels who are suitable for early salvage treatments. Two-year postradiotherapy biopsy results from a randomised controlled trial indicate that routine biopsy is not in...
Source: European Urology - January 4, 2018 Category: Urology & Nephrology Source Type: research

Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival
Conclusions While limited by the retrospective nature of the data, 5-yr DM is associated with lower OS following PORT, outperforming the prognostic capability of BF and CRPC at 1, 3, 5, or 7 yr after treatment. Confirmation of this ICE as a surrogate for OS is needed from randomized trial data so that it can be incorporated into future clinical trial design. Patient summary We assessed potential intermediate clinical endpoints prognostic for overall survival in a cohort of men receiving radiotherapy after prostatectomy. We identified the development of metastatic disease within 5 yr after treatment as the strongest predict...
Source: European Urology - January 3, 2018 Category: Urology & Nephrology Source Type: research

Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71]
Publication date: Available online 3 January 2018 Source:European Urology Author(s): Bernard Escudier, Padmanee Sharma, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Howard Gurney, Frede Donskov, Katriina Peltola, John Wagstaff, Thomas C. Gauler, Takeshi Ueda, Huanyu Zhao, Ian M. Waxman, Robert J. Motzer (Source: European Urology)
Source: European Urology - January 3, 2018 Category: Urology & Nephrology Source Type: research

Re: Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update
Publication date: Available online 26 December 2017 Source:European Urology Author(s): Alberto Bossi (Source: European Urology)
Source: European Urology - December 27, 2017 Category: Urology & Nephrology Source Type: research

Postchemotherapy Surgery for Advanced Urothelial Cancer: Another Tool To Improve Outcome
Publication date: Available online 27 December 2017 Source:European Urology Author(s): Bernard H. Bochner (Source: European Urology)
Source: European Urology - December 27, 2017 Category: Urology & Nephrology Source Type: research

Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor- β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease
This study verified that PSMA-specific, TGF-ß insensitive CD8+ T-cells derived from mCRPC patients could be successfully expanded and used to overcome the immunosuppressive effects of the tumor microenvironment to control PSMA-expressing PC in vitro and in vivo. This may provide a promising approach for men with mCRPC who fail androgen deprivation therapy. Patient summary We investigated the role of a novel chimeric antigen receptor T-immunotherapy based on autologous metastatic castrate-resistant prostate cancer patient-derived prostate-specific membrane antigen (PSMA)-specific, transforming growth factor-ß in...
Source: European Urology - December 22, 2017 Category: Urology & Nephrology Source Type: research

A Partner in Crime: Tumor-associated Stroma and Metastatic Prostate Cancer
Publication date: Available online 22 December 2017 Source:European Urology Author(s): Michael Fraser, Paul C. Boutros, Robert G. Bristow (Source: European Urology)
Source: European Urology - December 22, 2017 Category: Urology & Nephrology Source Type: research

Re: Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy
Publication date: Available online 21 December 2017 Source:European Urology Author(s): Joseph L. Chin (Source: European Urology)
Source: European Urology - December 21, 2017 Category: Urology & Nephrology Source Type: research

Re: Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy Versus External Beam Radiation
Publication date: Available online 21 December 2017 Source:European Urology Author(s): Mack Roach (Source: European Urology)
Source: European Urology - December 21, 2017 Category: Urology & Nephrology Source Type: research

Re: Positron Emission Tomography/Computed Tomography-based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-resistant Prostate Cancer
Publication date: Available online 21 December 2017 Source:European Urology Author(s): Bernardo Rocco, Ahmed Eissa, Giampaolo Bianchi (Source: European Urology)
Source: European Urology - December 21, 2017 Category: Urology & Nephrology Source Type: research

Re: Comprehensive Molecular Characterization of Muscle-invasive Bladder Cancer
Publication date: Available online 20 December 2017 Source:European Urology Author(s): Ryoichi Saito, Takashi Kobayashi, Osamu Ogawa (Source: European Urology)
Source: European Urology - December 20, 2017 Category: Urology & Nephrology Source Type: research

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens
Conclusions Atezolizumab demonstrated comparable efficacy and safety in previously treated patients with mUC across all lines of therapy evaluated. Patient summary We investigated effects of previous treatment in patients with metastatic urothelial carcinoma that progressed after platinum-based therapy. Atezolizumab was active and tolerable no matter how many treatment regimens patients had received. ClinicalTrials.gov, NCT02108652. Outcomes by prior regimens were examined in a phase 2 atezolizumab study in platinum-treated urothelial carcinoma. Atezolizumab demonstrated comparable efficacy and safety in previously treated...
Source: European Urology - December 20, 2017 Category: Urology & Nephrology Source Type: research

Prostate Artery Embolisation: Poor Design and Reporting Impact the Value of Current Systematic Reviews
Publication date: Available online 20 December 2017 Source:European Urology Author(s): Thomas D. Vreugdenburg, Alun L. Cameron, Claudia Wild (Source: European Urology)
Source: European Urology - December 20, 2017 Category: Urology & Nephrology Source Type: research

Re: What Are We Missing? False-negative Cancers at Multiparametric MR Imaging of the Prostate
Publication date: Available online 19 December 2017 Source:European Urology Author(s): Tine Hajdinjak, Alexandre E. Pelzer (Source: European Urology)
Source: European Urology - December 19, 2017 Category: Urology & Nephrology Source Type: research

Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve —Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases
Conclusions The results from this updated analysis demonstrate that RARP can be beneficial for patients of high-volume surgeons, although more randomised studies and studies with survival outcomes are needed. Patient summary Robot-assisted radical prostatectomy was able to improve functional and oncological outcomes in this single surgeon's learning curve. This observational study using prospectively collected follow-up and patient-reported outcome data showed that robot-assisted radical prostatectomy is able to obtain superior urinary, sexual, positive surgical margin, and biochemical control outcomes compared with open r...
Source: European Urology - December 19, 2017 Category: Urology & Nephrology Source Type: research

Re: Bimal Bhindi, Igor Frank, Ross J. Mason, et al. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur Urol 2017;72:660 –4
Publication date: Available online 19 December 2017 Source:European Urology Author(s): Georgios Papadopoulos, Charalampos Fragkoulis, Konstantinos Ntoumas (Source: European Urology)
Source: European Urology - December 19, 2017 Category: Urology & Nephrology Source Type: research

Re: Radical Cystectomy (Bladder Removal) Against Intravesical BCG Immunotherapy for High-risk Non-muscle Invasive Bladder Cancer (BRAVO): A Protocol for a Randomised Controlled Feasibility Study
Publication date: Available online 19 December 2017 Source:European Urology Author(s): Karl H. Pang, Aidan P. Noon (Source: European Urology)
Source: European Urology - December 19, 2017 Category: Urology & Nephrology Source Type: research

Re: Active Surveillance in Younger Men with Prostate Cancer
Publication date: Available online 19 December 2017 Source:European Urology Author(s): Haluk Özen, Levent N. Türkeri (Source: European Urology)
Source: European Urology - December 19, 2017 Category: Urology & Nephrology Source Type: research

Re: Molecular Classification of Urothelial Carcinoma: Global mRNA Classification Versus Tumour-cell Phenotype Classification
Publication date: Available online 19 December 2017 Source:European Urology Author(s): Ralph Peeker (Source: European Urology)
Source: European Urology - December 19, 2017 Category: Urology & Nephrology Source Type: research

Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study
Conclusions In comparison with previous studies, the difference in prostate cancer mortality after RT and RP was much smaller. Patient summary The difference in prostate cancer mortality after contemporary radiotherapy and radical prostatectomy was small in contrast to previous studies, indicating that potential side effects should be more emphasized when selecting treatment. There was no clinically relevant difference in the risk of prostate cancer death after radiotherapy compared with radical prostatectomy in an up-to-date analysis with comprehensive adjustment for confounders. (Source: European Urology)
Source: European Urology - December 16, 2017 Category: Urology & Nephrology Source Type: research

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting
Conclusions This article highlights the state of knowledge and outlines the most pressing questions that need to be addressed to advance the AR-V field. Patient summary Although further investigation is needed to delineate the role of androgen receptor (AR) variants in metastatic castration-resistant prostate cancer, advances in measurement science have enabled development of blood-based tests for treatment selection. Detection of AR variants (eg, AR-V7) identified a patient population with poor outcomes to existing AR-targeting therapies, highlighting the need for novel therapeutic agents currently under development. Prec...
Source: European Urology - December 16, 2017 Category: Urology & Nephrology Source Type: research

Re: Association Between Lymph Node Yield and Survival Among Patients Undergoing Radical Nephroureterectomy for Urothelial Carcinoma of the Upper Tract
Publication date: Available online 14 December 2017 Source:European Urology Author(s): Firas G. Petros, Surena F. Matin (Source: European Urology)
Source: European Urology - December 15, 2017 Category: Urology & Nephrology Source Type: research

A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma
Conclusions The CCP score is a significant, independent predictor of long-term oncologic outcomes in patients who have undergone nephrectomy for RCC. Combining the molecular classifier with baseline clinical variables allows for accurate, patient-specific risk assessment for use in guiding clinical management. Patient summary In this study, we sought to understand how well gene expression information from individual kidney tumors can predict cancer recurrence and death following surgical removal. We found that the combination of the gene expression test and clinical characteristics provides an accurate prognostic assessmen...
Source: European Urology - December 15, 2017 Category: Urology & Nephrology Source Type: research

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes
Conclusions GC+ipilimumab did not achieve the primary endpoint of a lower bound of the 90% confidence interval for 1-yr OS of >60%. However, within the context of a small single-arm trial, the results may inform current approaches combining chemotherapy plus immunotherapy from the standpoint of feasibility, appropriate cytotoxic backbones, and potential predictive biomarkers. Trial registration: ClinicalTrials.gov NCT01524991. Patient summary Combining chemotherapy and immune checkpoint blockade in patients with metastatic urothelial cancer is feasible. Further studies are needed to refine optimal combinations and e...
Source: European Urology - December 14, 2017 Category: Urology & Nephrology Source Type: research

Reply to Georgios Papadopoulos, Charalampos Fragkoulis, and Konstantinos Ntoumas ’ Letter to the Editor re: Bimal Bhindi, Igor Frank, Ross J. Mason, et al. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur Urol 2017;72:660–4
Publication date: Available online 12 December 2017 Source:European Urology Author(s): Bimal Bhindi, Stephen A. Boorjian (Source: European Urology)
Source: European Urology - December 13, 2017 Category: Urology & Nephrology Source Type: research

[18F]-Fluorodeoxyglucose Positron Emission Tomography and Response to Therapy in Idiopathic Retroperitoneal Fibrosis
Publication date: January 2018 Source:European Urology, Volume 73, Issue 1 Author(s): Eugenia Accorsi Buttini, Federica Maritati, Augusto Vaglio (Source: European Urology)
Source: European Urology - December 13, 2017 Category: Urology & Nephrology Source Type: research

Re: Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer
Publication date: January 2018 Source:European Urology, Volume 73, Issue 1 Author(s): Vito Pansadoro, Aldo Brassetti (Source: European Urology)
Source: European Urology - December 13, 2017 Category: Urology & Nephrology Source Type: research

Re: Metastasis-free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
Publication date: January 2018 Source:European Urology, Volume 73, Issue 1 Author(s): Martin Spahn (Source: European Urology)
Source: European Urology - December 13, 2017 Category: Urology & Nephrology Source Type: research

Re: Salvage High-intensity Focused Ultrasound (HIFU) for Locally Recurrent Prostate Cancer After Failed Radiation Therapy: Multi-institutional Analysis of 418 Patients
Publication date: January 2018 Source:European Urology, Volume 73, Issue 1 Author(s): Guillaume Ploussard (Source: European Urology)
Source: European Urology - December 13, 2017 Category: Urology & Nephrology Source Type: research

Re: Impact of Radical Prostatectomy on Long-term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration
Publication date: January 2018 Source:European Urology, Volume 73, Issue 1 Author(s): Daniel W. Good, Alan S. McNeill (Source: European Urology)
Source: European Urology - December 13, 2017 Category: Urology & Nephrology Source Type: research

Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient-specific Molds to Correlate Images with Whole-mount Pathology
Publication date: January 2018 Source:European Urology, Volume 73, Issue 1 Author(s): Theo van der Kwast (Source: European Urology)
Source: European Urology - December 13, 2017 Category: Urology & Nephrology Source Type: research

A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease
Conclusions GPS is a strong independent predictor of long-term outcomes in clinically localized PCa in men treated with RP and may improve risk stratification for men with newly diagnosed disease. Patient summary Many prostate cancers are slow growing and unlikely to spread or threaten a man's life, while others are more aggressive and require treatment. Increasingly, doctors are using new molecular tests, such as the17-gene Genomic Prostate Score (GPS), which can be performed at the time of initial diagnosis to help determine how aggressive a given patient's cancer may be. In this study, performed in a large community-bas...
Source: European Urology - December 13, 2017 Category: Urology & Nephrology Source Type: research

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update
Conclusions These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. Patient summary Urothelial carcinoma of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis; appropriate diagnosis and management is most important. We present recommendations based on current evidence for optimal management. These guidelines provide infor...
Source: European Urology - December 13, 2017 Category: Urology & Nephrology Source Type: research

Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis
Conclusions Contemporary MRI shows excellent sensitivity and specificity for detection of bone metastasis in patients with prostate cancer. Using two or more imaging planes may further improve sensitivity. However, caution is needed in applying our results due to the heterogeneity among the included studies. Patient summary We reviewed studies using contemporary magnetic resonance imaging (MRI) for the detection of bone metastasis in prostate cancer patients. MRI shows excellent diagnostic performance in finding patients with bone metastasis. Contemporary magnetic resonance imaging shows excellent per-patient sensitivity a...
Source: European Urology - December 13, 2017 Category: Urology & Nephrology Source Type: research

Are We Ready for Adjuvant Sunitinib in High-risk Renal Cell Carcinoma?
Publication date: January 2018 Source:European Urology, Volume 73, Issue 1 Author(s): Jozefina Casuscelli, James J. Hsieh (Source: European Urology)
Source: European Urology - December 13, 2017 Category: Urology & Nephrology Source Type: research

Intravenous Mannitol Versus Placebo During Partial Nephrectomy in Patients with Normal Kidney Function: A Double-blind, Clinically-integrated, Randomized Trial
Conclusions Intraoperative 12.5g mannitol infusion during NSS has no demonstrable clinical benefit when compared with standardized fluid hydration in patients with normal preoperative renal function, and its use in this setting is not warranted. Patient summary In this randomized trial, patients with normal kidney function who received mannitol during surgery to remove part of their kidney had no better kidney function 6 mo after surgery than those who did not receive mannitol. We conclude that this routine practice should be discontinued. Using intravenous mannitol intraoperatively to mitigate the effects of renal ischemi...
Source: European Urology - December 13, 2017 Category: Urology & Nephrology Source Type: research

Bladder Cancer in the Elderly
Publication date: January 2018 Source:European Urology, Volume 73, Issue 1 Author(s): Marko Babjuk (Source: European Urology)
Source: European Urology - December 13, 2017 Category: Urology & Nephrology Source Type: research

Erectile Function Recovery After Surgery in Young Men with Low-risk Prostate Cancer: Probably Not Just a Matter of Age, Certainly Not the Main Point of Discussion
Publication date: January 2018 Source:European Urology, Volume 73, Issue 1 Author(s): Paolo Capogrosso, Francesco Montorsi (Source: European Urology)
Source: European Urology - December 13, 2017 Category: Urology & Nephrology Source Type: research

Improved Recovery of Erectile Function in Younger Men after Radical Prostatectomy: Does it Justify Immediate Surgery in Low-risk Patients?
Conclusions Small differences in erectile function recovery in younger men are offset by a longer period of time living with decreased postoperative function. Better erectile recovery in younger men should not be a factor used to recommend immediate surgery in patients suitable for active surveillance, even if crossover to surgery is predicted within a short period of time. Patient summary Younger men have better recovery of erectile function after surgery for prostate cancer. This has led to the suggestion that delaying surgery for low-risk disease may lead patients to miss a window of opportunity to recover erectile func...
Source: European Urology - December 13, 2017 Category: Urology & Nephrology Source Type: research

The Current State of Predicting Response on Bacillus Calmette-Gu érin Treatment for Nonmuscle Invasive Bladder Cancer is Not Yet Useful for Patients but Attributes to Understanding Its Mechanisms of Action
Publication date: Available online 2 December 2017 Source:European Urology Author(s): Jorg R. Oddens, Theo M. de Reijke (Source: European Urology)
Source: European Urology - December 10, 2017 Category: Urology & Nephrology Source Type: research

Port-site Metastases After Robot-assisted Radical Cystectomy: Is There a Publication Bias?
Publication date: Available online 2 December 2017 Source:European Urology Author(s): Georg Jancke, Firas Aljabery, Sigurdur Gudjonsson, Abolfazl Hosseini, Anne Sörenby, Peter Wiklund, Fredrik Liedberg (Source: European Urology)
Source: European Urology - December 10, 2017 Category: Urology & Nephrology Source Type: research

Re: Availability of Evidence of Benefits on Overall Survival and Quality of Life of Cancer Drugs Approved by European Medicines Agency: Retrospective Cohort Study of Drug Approvals 2009 –2013
Publication date: Available online 6 December 2017 Source:European Urology Author(s): Stephan Madersbacher, Gero Kramer (Source: European Urology)
Source: European Urology - December 10, 2017 Category: Urology & Nephrology Source Type: research

Re: Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer
Publication date: Available online 6 December 2017 Source:European Urology Author(s): Liang Dong, Kenneth J. Pienta (Source: European Urology)
Source: European Urology - December 10, 2017 Category: Urology & Nephrology Source Type: research

Re: Comprehensive Molecular Characterization of Muscle Invasive Bladder Cancer
Publication date: Available online 6 December 2017 Source:European Urology Author(s): Marcus G. Cumberbatch, James W.F. Catto (Source: European Urology)
Source: European Urology - December 10, 2017 Category: Urology & Nephrology Source Type: research

Re: Positive Surgical Margins and Local Recurrence After Simple Enucleation and Standard Partial Nephrectomy for Malignant Renal Tumors: Systematic Review of the Literature and Meta-analysis of Prevalence
Publication date: Available online 6 December 2017 Source:European Urology Author(s): Francesco Porpiglia, Riccardo Bertolo (Source: European Urology)
Source: European Urology - December 10, 2017 Category: Urology & Nephrology Source Type: research